ReviewFrontiers in immunology2018
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.Cancer immunology, immunotherapy : CII · 2020Trial
- Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment.Frontiers in oncology · 2023Review
- Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner.Biomedicines · 2022Article
- Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.International journal of molecular sciences · 2021Review
- Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.Cancers · 2021Review
- Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.Cancer medicine · 2021Review
- Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Macrophage Plasticity and Function in the Lung Tumour Microenvironment Revealed in 3D Heterotypic Spheroid and Explant Models.Biomedicines · 2021Article
- The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma.Journal of Cancer · 2021Review
- Metabolomic profiling of tumor-infiltrating macrophages during tumor growth.Cancer immunology, immunotherapy : CII · 2020Article
- Autophagy, the innate immune response and cancer.Molecular oncology · 2020Review
- Role of AHR in the control of GBM-associated myeloid cells.Seminars in cancer biology · 2020Review
- Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer.Cancers · 2020Article
- Cancer-associated V-ATPase induces delayed apoptosis of protumorigenic neutrophils.Molecular oncology · 2020Article
- Hypofractionated Irradiation Suppressed the Off-Target Mouse Hepatocarcinoma Growth by Inhibiting Myeloid-Derived Suppressor Cell-Mediated Immune Suppression.Frontiers in oncology · 2020Article
- A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment.Frontiers in immunology · 2020Review
- Immune-Related Gene Expression and Cytokine Secretion Is Reduced Among African American Colon Cancer Patients.Frontiers in oncology · 2020Article
- Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.BMC cancer · 2019Article
- Acute Lymphoblastic Leukaemia Cells Impair Dendritic Cell and Macrophage Differentiation: Role of BMP4.Cells · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic approaches that engage immune cells to treat cancer are becoming increasingly utilized in the clinics and demonstrated durable clinical benefit in several solid tumor types. Most of the current immunotherapies focus on manipulating T cells, however, the tumor microenvironment (TME) is abundantly infiltrated by a heterogeneous population of tumor-associated myeloid cells, including tumor-associated macrophages (TAMs), tumor-associated dendritic cells (TADCs), tumor-associated neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs). Educated by signals perceived in the TME, these cells often acquire tumor-promoting properties ultimately favoring disease progression. Upon appropriate stimuli, myeloid cells can exhibit cytoxic, phagocytic, and antigen-presenting activities thereby bolstering antitumor immune responses. Thus, depletion, reprogramming or reactivation of myeloid cells to either directly eradicate malignant cells or promote antitumor T-cell responses is an emerging field of interest. In this review, we briefly discuss the tumor-promoting and tumor-suppressive roles of myeloid cells in the TME, and describe potential therapeutic strategies in preclinical and clinical development that aim to target them to further expand the range of current treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.